サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777798

アスペルギルス症治療の世界市場

Aspergillosis Treatment

出版日
ページ情報
英文 374 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
アスペルギルス症治療の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 374 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アスペルギルス症治療の世界市場は2030年までに52億米ドルに到達

2024年に44億米ドルと推定されるアスペルギルス症治療の世界市場は、2024年から2030年にかけてCAGR 3.0％で成長し、2030年には52億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアレルギー性アスペルギルス症治療は、CAGR 3.4％を記録し、分析期間終了までに30億米ドルに達すると予測されます。慢性アスペルギルス症治療分野の成長率は、分析期間中CAGR 2.5％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 5.7％で成長予測

米国のアスペルギルス症治療市場は、2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.7%として、2030年までに10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.3%と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界のアスペルギルス症治療市場- 主要動向と促進要因まとめ

医療技術革新によるアスペルギルス症治療の改善とは？

アスペルギルス属に起因する真菌感染症であるアスペルギルス症は、免疫不全患者の間で蔓延しているため、重要な懸念事項となっています。トリアゾール系やエキノカンディン系などの抗真菌薬の進歩により、治療成績は大きく向上しました。また、併用療法やガラクトマンナン検査、PCR検査などの診断ツールの開発により、早期発見と個別化された治療計画が改善されています。さらに、新規抗真菌剤や標的ドラッグデリバリーシステムの研究により、耐性や副作用といった現在の治療法の限界に対処しつつあります。このような技術革新は、弱い立場にある人々により良い医療を提供するために、アスペルギルス症治療の状況を変えつつあります。

アスペルギルス症治療市場に影響を与える動向とは？

アスペルギルス症治療市場は、いくつかの重要な動向に牽引されて成長しています。免疫力を低下させる糖尿病やがんなどの慢性疾患の増加により、患者層が拡大しています。病院はリスクの高い患者に対して予防的抗真菌治療を採用し、予防の重要性を強調しています。多剤耐性真菌の増加により、先進的な抗真菌薬研究への投資も活発化しています。また、ジェネリック医薬品の登場により、特に新興国では治療がより身近なものとなっています。これらの動向は、アスペルギルス症が早急な対応を要する重要なヘルスケア課題であるとの認識が高まっていることを反映しています。

なぜアスペルギルス症の管理には早期診断が重要なのか？

アスペルギルス症の治療が遅れると、侵襲性感染症などの重篤な合併症を引き起こす可能性があるため、アスペルギルス症を効果的に管理するためには、適時の診断が極めて重要です。バイオマーカーアッセイや画像診断ツールなどの高度な診断技術により、臨床医はより早く、より正確に感染を特定できるようになってきています。このような進歩は、特に免疫不全の患者にとって重要です。ヘルスケアプロバイダーはまた、転帰を改善するために、啓発キャンペーンと定期的なスクリーニングを優先しています。診断ツールへのAIと機械学習の統合は、アスペルギルス症検出の精度と速度をさらに高め、患者ケアに大きな飛躍をもたらします。

アスペルギルス症治療市場の成長の原動力は？

アスペルギルス症治療市場の成長は、免疫不全状態の有病率の増加、診断技術の進歩、新規抗真菌療法の開発など、いくつかの要因によってもたらされます。ヘルスケア投資の増加や専門病院の拡大により、治療へのアクセスが向上しています。新規抗真菌薬の研究に対する規制当局の支援は技術革新を加速し、患者の意識向上プログラムは早期診断率を高めています。さらに、先進的な併用療法が利用できるようになったことで、患者の予後が改善し、今後数年間の市場の堅調な成長が見込まれています。

セグメント

タイプ（アレルギー性アスペルギルス症治療,慢性アスペルギルス症治療,侵入性アスペルギルス症治療）;薬剤クラス（抗真菌薬,その他薬剤クラス別）;流通チャネル（病院薬局流通チャネル,小売薬局流通チャネル,その他流通チャネル）

調査対象企業の例

  • Astellas Pharma US, Inc.
  • Basilea Pharmaceutica Ltd.
  • Bioseutica BV
  • F2G Ltd.
  • ImmuPharma
  • Mayne Pharma Group Ltd.
  • Pulmatrix, Inc.
  • Pulmocide Ltd.
  • SCYNEXIS, Inc.
  • Shionogi & Co., Ltd.

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29290

Global Aspergillosis Treatment Market to Reach US$5.2 Billion by 2030

The global market for Aspergillosis Treatment estimated at US$4.4 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Allergic Aspergillosis Treatment, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Chronic Aspergillosis Treatment segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 5.7% CAGR

The Aspergillosis Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Aspergillosis Treatment Market - Key Trends & Drivers Summarized

How Is Medical Innovation Improving Aspergillosis Treatment?

Aspergillosis, a fungal infection caused by Aspergillus species, has become a significant concern due to its prevalence among immunocompromised patients. Advances in antifungal drugs, such as triazoles and echinocandins, have greatly enhanced treatment outcomes. The development of combination therapies and diagnostic tools, including galactomannan tests and PCR assays, has improved early detection and personalized treatment plans. Additionally, research into novel antifungal agents and targeted drug delivery systems is addressing the limitations of current therapies, such as resistance and side effects. These innovations are transforming the landscape of aspergillosis treatment, ensuring better care for vulnerable populations.

What Trends Are Influencing the Aspergillosis Treatment Market?

The aspergillosis treatment market is witnessing growth driven by several key trends. The increasing prevalence of chronic diseases like diabetes and cancer, which weaken the immune system, has expanded the patient pool. Hospitals are adopting prophylactic antifungal treatments for high-risk patients, emphasizing the importance of prevention. The rise of multi-drug-resistant fungal strains has spurred investment in advanced antifungal research. Additionally, the availability of generic formulations has made treatments more accessible, particularly in emerging economies. These trends reflect the growing recognition of aspergillosis as a critical healthcare challenge requiring urgent attention.

Why Is Early Diagnosis Crucial in Managing Aspergillosis?

Timely diagnosis is pivotal in managing aspergillosis effectively, as delayed treatment can lead to severe complications, including invasive infections. Advanced diagnostic techniques, such as biomarker assays and imaging tools, are enabling clinicians to identify the infection earlier and with greater accuracy. These advancements are particularly important for immunocompromised patients, who are at heightened risk. Healthcare providers are also prioritizing awareness campaigns and routine screenings to improve outcomes. The integration of AI and machine learning into diagnostic tools is further enhancing the accuracy and speed of aspergillosis detection, marking a significant leap forward in patient care.

What Drives the Growth in the Aspergillosis Treatment Market?

The growth in the aspergillosis treatment market is driven by several factors, including the increasing prevalence of immunocompromised conditions, advancements in diagnostic technologies, and the development of novel antifungal therapies. Rising healthcare investments and the expansion of specialty hospitals are providing greater access to treatment. Regulatory support for research into new antifungal agents is accelerating innovation, while patient awareness programs are boosting early diagnosis rates. Additionally, the availability of advanced combination therapies is improving patient outcomes, ensuring robust market growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Aspergillosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment, Invasive Aspergillosis Treatment); Drug Class (Antifungal Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Astellas Pharma US, Inc.
  • Basilea Pharmaceutica Ltd.
  • Bioseutica BV
  • F2G Ltd.
  • ImmuPharma
  • Mayne Pharma Group Ltd.
  • Pulmatrix, Inc.
  • Pulmocide Ltd.
  • SCYNEXIS, Inc.
  • Shionogi & Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Aspergillosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Invasive Fungal Infections Drives Demand for Treatment Options
    • Growing Immunocompromised Patient Population Fuels Market Growth
    • Advances in Antifungal Drug Development Improve Clinical Outcomes
    • Increased Use of Diagnostic Tools for Early Detection Supports Timely Intervention
    • Expansion of Hospital Infrastructure in Developing Countries Enhances Treatment Access
    • Rising Awareness of Fungal Infection Management Among Healthcare Providers Boosts Demand
    • Improved Drug Delivery Mechanisms Enhance Therapeutic Efficacy
    • Surge in Organ Transplant and Cancer Treatments Increases Risk of Aspergillosis
    • Growth in Research on Antifungal Resistance Promotes Innovation in Drug Discovery
    • Emergence of Combination Therapies Improves Treatment Response
    • Biotech Startups and Pharma Companies Expanding Antifungal Pipelines Drive Market Entry
    • Increasing Adoption of Prophylactic Therapies in High-Risk Patients Encourages Market Expansion
    • Government and Institutional Funding for Rare Infection Treatment Enhances R&D
    • Growing Role of Telemedicine in Aspergillosis Management Expands Market Reach
    • Advancements in Inhalable Antifungals Support Non-Invasive Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Aspergillosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Allergic Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Allergic Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Allergic Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chronic Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Invasive Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Invasive Aspergillosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Invasive Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Aspergillosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Aspergillosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Aspergillosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Aspergillosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Aspergillosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Aspergillosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Aspergillosis Treatment by Type - Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Aspergillosis Treatment by Type - Percentage Breakdown of Value Sales for Allergic Aspergillosis Treatment, Chronic Aspergillosis Treatment and Invasive Aspergillosis Treatment for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Aspergillosis Treatment by Drug Class - Antifungal Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Aspergillosis Treatment by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Aspergillosis Treatment by Distribution Channel - Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Aspergillosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION